Skip to main content
Go to the home page of the European Commission (opens in new window)
English en
CORDIS - EU research results
CORDIS

Receptor-Focused Interventions Against Orthoflavivirus Neuroinvasion and Entry

Project description

Enhancing Europe’s response to mosquito-borne viruses

Mosquito-borne diseases like the West Nile and Usutu viruses are becoming a growing threat to public health in Europe. These viruses are spreading more widely, and current treatments are limited. With climate change and increased mosquito populations, the risk of outbreaks is rising. There is an urgent need for effective solutions to prevent and treat these infections. With this in mind, the EU-funded REFINE project will develop treatments. It focuses on understanding how the viruses interact with the human body and identifying targets for drugs and vaccines. The project uses advanced models to test the safety of potential treatments. Ultimately, REFINE aims to improve Europe’s ability to respond quickly to these viral threats.

Objective

REFINE confronts the escalating challenge of mosquito-borne orthoflavivirus infections, focusing on West Nile and Usutu viruses as emergent threats to European public health. The overall goal is to identify novel targets for therapeutics and to deliver a suite of validated models to assess efficacy and safety of novel compounds (antibodies, inhibitors, and vaccine candidate targets) for Phase I clinical trials. In the first of its six experimental objectives, REFINE characterizes genomic diversity of orthoflaviviruses to select representative clinically relevant strains. A unique strength of the proposal is the extensive suite of model assays (objective 2) designed to unravel the complex dynamics of virus-host interactions at each step of the infection pathway. These assays form a basis for receptor and pathway characterisation (objective 3). Objective 4 aims to asses both efficacy and safety of novel intervention strategies targeting these receptors and pathways, based on nanobodies, peptides and monoclonal antibodies. Objective 5 studies the key infection steps and putative receptors in humans, utilizing previously collected patient samples to ensure real-world applicability of developed strategies. Ultimately, objective 6 is to integrate knowledge gained to establish a robust and sustainable platform capable of rapid validation of new therapeutic interventions.

The overall mission of REFINE is to significantly enhance Europe's preparedness and response abilities against the expected wave of mosquito-borne viral diseases. The team members share a lifelong commitment to advancing our understanding of the molecular mechanisms underlying various aspects of host-pathogen interactions at the human-animal-environment interface. Together, the REFINE team embodies a comprehensive approach to address one of the priority health security concerns of our time by delivering effective and safe countermeasures against emergent viral pathogens in Europe.

Fields of science (EuroSciVoc)

This project has not yet been classified with EuroSciVoc.
Be the first one to suggest relevant scientific fields and help us improve our classification service

Keywords

Programme(s)

Topic(s)

Funding Scheme

HORIZON-RIA - HORIZON Research and Innovation Actions

See all projects funded under this funding scheme

Call for proposal

(opens in new window) HORIZON-HLTH-2024-DISEASE-08

See all projects funded under this call

Coordinator

ERASMUS UNIVERSITAIR MEDISCH CENTRUM ROTTERDAM
Net EU contribution
€ 2 940 945,50
Address
DR MOLEWATERPLEIN 40
3015 GD Rotterdam
Netherlands
Activity type
Higher or Secondary Education Establishments
Links
Total cost
€ 2 940 945,50

Participants (4)

Partners (2)